KFDA okayed Iressa sales in Korea.

Published: 2003-06-18 06:59:00

Updated: 2003-06-18 06:59:00

The KFDA approved Iressa, a non-small lung cancer drug developed by Astra Zeneca on June 14 after clearing the comparative dissolution test problems.

The registration in Korea will be the 6th after Japan, America, Australia, Singapore and Argentina for the treatment of non-small lung cancer of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK